Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. - Wikidata - wikimedia - TriplyDB

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

http://www.wikidata.org/entity/Q46217486

about

KASL clinical practice guidelines: management of chronic hepatitis B Genetic variation of hepatitis B virus and its significance for pathogenesis Hepatitis B virus therapy: What's the future holding for us?Clinical Advances in Fibrosis Progression of Chronic Hepatitis B and C The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs Current and future directions for treating hepatitis B virus infection Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation Hepatitis B virus treatment beyond the guidelines: special populations and consideration of treatment withdrawal Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines Antiviral therapy for chronic hepatitis B in China Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis Direct acting antivirals for the treatment of chronic viral hepatitis Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B Treatment strategies according to genotype for chronic hepatitis B in children Antiviral drug resistance: mechanisms and clinical implications Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection.Recent advances in micro/nanotechnologies for global control of hepatitis B infection Current hepatitis B treatment guidelines and future research directions.Using multiple imputation to estimate cumulative distribution functions in longitudinal data analysis with data missing at random.Hepatitis B Virus Immunopathology, Model Systems, and Current Therapies Hepatitis B virus infection and alcohol consumption Efficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues: A Prospective Study.Chronic hepatitis B: Advances in treatment.Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions.Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study.TDF Monotherapy Is Effective Regardless of Prior Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patients in China.Trends in all cause and viral liver disease-related hospitalizations in people with hepatitis B or C: a population-based linkage study A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B.Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B.Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelines Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B.Sequences in the terminal protein and reverse transcriptase domains of the hepatitis B virus polymerase contribute to RNA binding and encapsidation Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials.

P2860

Q26752475-C6CDEC98-CA34-4161-B28A-81B647084719 Q26772348-DEB6026A-E5EE-4FAF-A88F-AF42BE6CB72F Q26774198-8DA94221-F4AA-4A0D-923E-BF8CA082124A Q26781789-B80E6CE2-5A40-411B-900E-2CEE3759BC6E Q26781795-A32A41BC-2FFE-44BE-92EC-040217B2157E Q26851240-614DD809-512E-45A0-AFC7-DD8937447708 Q26864647-8854E684-8F12-4C51-A595-ADF6D45F0C8B Q26995814-41121E7C-1E22-4AA7-9089-1459E4C06027 Q26995852-CE72E638-6992-4337-9484-63815B20DD51 Q27000080-A883A9DA-179A-43A5-BCA7-EAA299B96E08 Q27006557-5CBB1C1A-035E-4668-A1C6-D5398885CEC0 Q27008984-6D10C06C-055C-4484-8E31-CE484FA6BF57 Q27016075-7B247ABC-E39F-4B62-9A1B-03412BCC30E4 Q27022216-B9A37F97-D859-4DEE-9DFC-D67212DCA7C2 Q27030828-FF40ED02-D34D-4727-A6D5-3F9DB416BCB9 Q28066476-F0CEA05F-261D-452F-B50E-108E23A849BB Q28282376-C1C79E73-961D-4F63-B669-3DC265C4526F Q28468387-E8EF3BD8-0EE9-4760-85F1-8F963B02AE24 Q28485228-1438A65D-37C2-45DD-A71A-7F9380049C1B Q28540372-A0F35FFB-9BB3-48C4-BFA2-C75434EA7BDE Q30244767-0DA115CF-98F2-434D-87F9-54C5201182B9 Q30394611-A562CCF6-B11E-4AF1-B6E9-50952335A7E0 Q30487002-B28C9788-970C-4B7F-B865-ECAAF81C8EC0 Q30665870-F575AD5A-4F04-40BF-A359-DE277EFAB955 Q33559657-F20E18BE-81C5-4EF2-AE13-1084F3B435FD Q33599503-C341B017-42E9-4123-A689-A1D60A4F1D02 Q33608997-2A58C9F3-0C1F-4CA0-98AE-F8C2C8E750EF Q33660010-0D193DD4-1AE4-49DE-BB50-BB5FE704665D Q33676349-9EB44908-F128-49C4-81AC-2366697A7A45 Q33718958-8DB103A0-CD78-4B37-B1A8-C60A59267D3D Q33746790-6E0A1BEE-A8B9-45ED-AFE9-37A3155DAD50 Q33800724-A284EE59-8BF1-4446-8018-CAC1E7E97BC9 Q33801743-F525687B-79DC-4123-9F14-F7B3F08F2B79 Q33819098-D318DDC1-27FE-48C2-B35F-0F46B6F52D73 Q33819124-61E6F142-0B96-4684-A5C4-98A72FA19EEF Q33855708-D563EC4A-AB48-42F0-A037-745BCF3C3412 Q33872988-BDBB7FCD-51CC-49A5-A10E-DFD0D175CAF6 Q33875691-A75F33A6-F3D7-4BFF-AE81-43A317EA256F Q33911464-15E1BE3F-429D-4693-9F8D-C4664D84968B Q33926126-AEF9CE1D-6BE8-4011-88EA-A08746A7FCDC

P2860

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

http://www.wikidata.org/entity/Q46217486

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

@en

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

@nl

type

label

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

@en

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

@nl

prefLabel

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

@en

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

@nl

P1433

Q46217486-210C98DB-A28C-4CD3-88C4-89BA7C3D92E7

P1476

Q46217486-E2E3F67B-9252-4F3D-BD98-FBCFF5E11A03

P2093

Q46217486-0A56CF34-F551-4939-B808-49684D1A7BBC

Q46217486-0BFEEE43-B0B0-49A6-8339-A09051C47CA7

Q46217486-10437DDB-603B-43E4-92CE-FEBC58DE94BB

Q46217486-12FA95DD-1B82-4E0B-88E3-E706117EDF30

Q46217486-14489AA0-7EE4-4882-A497-FCC44AFB1E46

Q46217486-15959356-ACD7-4847-B319-19B2B47415CE

Q46217486-15BF1333-687C-4B32-80F9-72CFA17CDC98

Q46217486-1B371C49-2E65-4F6C-A93A-01913EB20197

Q46217486-20E712AC-B66E-49C9-B3B4-60BE6AF2D466

Q46217486-270BF750-4AB7-4553-B80E-26B20E2FC3D2

P304

Q46217486-F627E06B-38A2-4D14-AAB9-7929B63C0B60

P31

Q46217486-C66C9262-AA00-4C25-9376-D9134C7B17EA

P356

Q46217486-0DB623D5-5596-407E-9260-A05D5FE27F0B

P407

Q46217486-BCFBC4BD-E027-4294-8F7C-F963E3AC9313

P433

Q46217486-E06D1918-6D9D-4A36-871A-83D20BDC6DC0

P478

Q46217486-535A3E1A-1CC1-464C-AAAF-364206E6F2E7

P50

Q46217486-DB1D4AE6-B874-41C5-A408-8CF9B5F78522

Q46217486-EB723F18-581D-4C25-8FF6-8DD8A0A5A9FD

P577

Q46217486-C2F2E0CD-3FE2-4273-900D-9C2978F72FFA

P698

Q46217486-31ED2B00-3A41-4322-9004-35666FAAD9E3

P356

P1433

The New England Journal of Medicine

P1476

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

@en

P2093

Andrea Snow-Lampart

http://www.w3.org/2001/XMLSchema#string

E Jenny Heathcote

http://www.w3.org/2001/XMLSchema#string

Ed Gane

http://www.w3.org/2001/XMLSchema#string

Elsa Mondou

http://www.w3.org/2001/XMLSchema#string

Franck Rousseau

http://www.w3.org/2001/XMLSchema#string

Frank Weilert

http://www.w3.org/2001/XMLSchema#string

George Germanidis

http://www.w3.org/2001/XMLSchema#string

Huy Trinh

http://www.w3.org/2001/XMLSchema#string

Iskren Kotzev

http://www.w3.org/2001/XMLSchema#string

Jane Anderson

http://www.w3.org/2001/XMLSchema#string

P304

2442-2455

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA0802878

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

359

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19052126

http://www.w3.org/2001/XMLSchema#string